Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment
Annals of Laboratory Medicine · 01.05.2023 · 43 (3) · 221-222
DOI: 10.3343/alm.2023.43.3.221 ↗Kurz gefasst
Editorial in der Zeitschrift Annals of Laboratory Medicine, online erschienen am 22.12.2022. Verfasst von Yeo-Min Yun. Beteiligte Einrichtung: Konkuk University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Atherosclerosis. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Despite evidence for the superiority of non-HDL cholesterol (HDLC) and apolipoprotein B (Apo B) in the accurate estimation of atherosclerotic cardiovascular disease (ASCVD) risk [1-4], LDL cholesterol (LDL-C) remains the primary marker recommended in major lipid guidelines to judge treatment adequacy [5, 6]. NonHDL-C values are calculated by subtracting the HDL-C level from the total cholesterol level, which can reflect LDL-C levels as well as very low-density lipoprotein cholesterol (VLDL-C), intermediate-density lipoprotein cholesterol (IDL-C), remnant parts, and lipoprotein (a) [Lp (a)] levels [7]. Apo B is the main protein that makes up LDL-C, VLDL-C, IDL-C, and Lp (a). All lipoprotein particles have a single Apo B molecule; therefore, when Apo B is measured, it is possible to check the number of VLDL-C, IDL-C, and Lp (a) particles, including LDL-C, as ASCVD risk factors [2]. Trapping of Apo B in the arterial wall is the main cause of ASCVD, and cholesterol is the only proatherogenic element deposited after Apo B is trapped in the arterial wall. Oxidized phospholipids and Apo B are powerful inducers of inflammation, damage, and angiogenesis, and Apo B particles are fundamental factors in arterial wall injury [2, 4]. Since VLDL particles are also atherogenic and Apo B levels can reflect the number of VLDL particles as well as LDL, the Apo B level can be used to more accurately assess ASCVD risk than LDL-C and non-HDL-C levels [1, 2, 4, 6]. The 2019 European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) guidelines suggest that Apo B can more accurately measure ASCVD risk and the adequacy of lipid-lowering treatment than LDL-C or non-HDL-C and that Apo B can also be measured more accurately than LDL-C and nonHDL-C [6]. However, owing to the very high correlations among LDL-C, non-HDL-C, and Apo B, it has been suggested that Apo B may in fact not be superior to non-HDL-C and LDL-C for risk assessment [8, 9]. In this issue of Annals of Laboratory Medicine, Yun, et al. [10] report that the Apo B level can serve a useful marker for ASCVD risk assessment in patients with ASCVD risk factors, even those presenting normal LDL-C levels. Because LDL-C, non-HDL-C, and Apo B are highly correlated, it is very difficult to distinguish their individual relationships with ASCVD risk using a general statistical analysis method. Discordance analysis can be used to compare highly correlated variables, which could enable comparison between patients with average and discordant (higher or lower than average) cholesterol mass per Apo B particle [2, 11]. Johannesen, et al. [1] conducted the first discordance analysis in patients treated with a statin for myocardial infarction and assessed death risk according to discordant Apo B, non-HDL-C, and LDL-C levels. They found that high Apo B or non-HDL-C but low LDL-C levels were associated with an increased risk of ASCVD and mortality, whereas high LDL-C but low Apo B or non-HDL-C levels did not show an association. High Apo B/low non-HDL-C was associated with a higher all-cause risk than low 1 / 1 CROSSMARK_logo_3_Test
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Konkuk University School of Medicine, Seoul, Korea.
ORCID-Profile: Yeo-Min Yun
Zitieren
APA
Yun, Y. M. (2023). Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment. Annals of Laboratory Medicine, 43(3), 221-222. https://doi.org/10.3343/alm.2023.43.3.221
Vancouver
Yun YM. Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment. Annals of Laboratory Medicine. 2023;43(3):221-222. doi:10.3343/alm.2023.43.3.221
BibTeX
@article{Yun2023,
author = {Yun, Yeo-Min},
title = {Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment},
journal = {Annals of Laboratory Medicine},
year = {2023},
volume = {43},
number = {3},
pages = {221--222},
doi = {10.3343/alm.2023.43.3.221}
}
EUVIMED